Literature DB >> 18196608

A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells.

Zuo-Fu Peng1, Lin-Xiang Lan, Fang Zhao, Jing Li, Qiang Tan, Han-Wei Yin, Hui-Hui Zeng.   

Abstract

Human thioredoxin reductase (TrxR) system is associated with cancer cell growth and anti-apoptosis process. Effects of 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]ethane (BBSKE), a novel TrxR inhibitor, were investigated on human leukemia cell lines HL-60 and K562. BBSKE treatment induced cell growth inhibition and apoptosis in both cell lines. Apoptosis induced by BBSKE is through Bcl-2/Bax and caspase-3 pathways. Ehrlich's ascites carcinoma-bearing mice were used to investigate the anti-tumor effect of BBSKE in vivo. Tumor-bearing mice treated with BBSKE showed an increase of life span with a comparable effect to cyclophosphamide (CTX). These results suggest a potential usage of BBSKE as a therapeutic agent against non-solid tumors.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18196608      PMCID： PMC2170464          DOI： 10.1631/jzus.B071605

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN： 1673-1581            Impact factor:   3.066


  25 in total

1.  The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: possible involvement of nuclear factor-kappaB-dependent pathway.

Authors:  Linxiang Lan; Fang Zhao; Yan Wang; Huihui Zeng
Journal:  Eur J Pharmacol       Date:  2006-10-21       Impact factor: 4.432

2.  Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma.

Authors:  K Kahlos; Y Soini; M Säily; P Koistinen; S Kakko; P Pääkkö; A Holmgren; V L Kinnula
Journal:  Int J Cancer       Date:  2001-05-20       Impact factor: 7.396

3.  Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma.

Authors:  Y Soini; K Kahlos; U Näpänkangas; R Kaarteenaho-Wiik; M Säily; P Koistinen; P Pääakkö; A Holmgren; V L Kinnula
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

4.  Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer.

Authors:  S Kakolyris; A Giatromanolaki; M Koukourakis; G Powis; J Souglakos; E Sivridis; V Georgoulias; K C Gatter; A L Harris
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

5.  Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma.

Authors:  A Söderberg; B Sahaf; A Rosén
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

6.  Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase.

Authors:  Linda Björkhem-Bergman; Kerstin Jönsson; Lennart C Eriksson; Jerker M Olsson; Sören Lehmann; Christer Paul; Mikael Björnstedt
Journal:  Biochem Pharmacol       Date:  2002-05-15       Impact factor: 5.858

7.  Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication.

Authors:  L Shao; M B Diccianni; T Tanaka; R Gribi; A L Yu; J D Pullen; B M Camitta; J Yu
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 8.  The role of the redox protein thioredoxin in cell growth and cancer.

Authors:  G Powis; D Mustacich; A Coon
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

9.  A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines.

Authors:  Changjin Shi; Lizhang Yu; Fengguang Yang; Jun Yan; Huihui Zeng
Journal:  Biochem Biophys Res Commun       Date:  2003-09-26       Impact factor: 3.575

10.  Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival.

Authors:  Jennifer Raffel; Achyut K Bhattacharyya; Alfred Gallegos; Haiyan Cui; Janine G Einspahr; David S Alberts; Garth Powis
Journal:  J Lab Clin Med       Date:  2003-07
View more
  3 in total

1.  Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest.

Authors:  Jia-Ning Fu; Jing Li; Qiang Tan; Han-Wei Yin; Kun Xiong; Tian-Yu Wang; Xiao-Yuan Ren; Hui-Hui Zeng
Journal:  Invest New Drugs       Date:  2010-03-02       Impact factor: 3.850

2.  Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo.

Authors:  Qiang Tan; Jing Li; Han-wei Yin; Li-hui Wang; Wan-chen Tang; Fang Zhao; Xin-min Liu; Hui-hui Zeng
Journal:  Invest New Drugs       Date:  2009-03-07       Impact factor: 3.850

3.  Availability and toxicity of Fe(II) and Fe(III) in Caco-2 cells.

Authors:  Wan-ling He; Ying Feng; Xiao-li Li; Yan-yan Wei; Xiao-e Yang
Journal:  J Zhejiang Univ Sci B       Date:  2008-09       Impact factor: 3.066
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.